Compare LYNX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYNX | DMRA |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2026 | 2020 |
| Metric | LYNX | DMRA |
|---|---|---|
| Price | $11.42 | $19.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $19.67 | ★ $46.89 |
| AVG Volume (30 Days) | 459.1K | ★ 739.6K |
| Earning Date | 11-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 121.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.28 | N/A |
| Revenue Next Year | $34.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.20 | $16.50 |
| 52 Week High | $14.64 | $34.89 |
| Indicator | LYNX | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 30.51 | 36.78 |
| Support Level | N/A | $18.73 |
| Resistance Level | $13.74 | $26.76 |
| Average True Range (ATR) | 0.65 | 1.28 |
| MACD | -0.12 | 0.23 |
| Stochastic Oscillator | 1.75 | 52.25 |
Lyntris Inc is a defense technology company that develops connectivity solutions for military applications. Its products consist of interconnected subsystems designed to support defense and military customers in detecting threats, making decisions, and responding to operational requirements across multi-domain environments. The company serves U.S. and allied nation military customers. Its solutions are deployed across three core missions: Maritime Domain Awareness; Air & Missile Defense; and Space ISR & Resilient Communications. Maximum revenue is derived from the Maritime Domain Awareness business, which includes solutions focused on maritime monitoring, tracking and analysis that support government and defense customers in maintaining situational awareness across maritime environments.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.